Skip to main content

Mount Sinai Partners to Develop COVID-19 Hyperimmune Globulin

Hyperimmune Treatment Infographic
Credit: Emergent BioSolutions

Mount Sinai Health System and Emergent BioSolutions are conducting clinical trials to evaluate COVID-19 immunoglobulin in a post-exposure prophylaxis study in individuals at high risk of exposure to COVID-19, such as front-line health care workers and military personnel. ImmunoTek Bio Centers will provide technical, scientific, and industry expertise in plasma collection and will extend its FDA license as an approved source plasma collection establishment to enable plasma collection onsite at Mount Sinai.

Learn More